Juno Therapeutics
http://dbpedia.org/resource/Juno_Therapeutics an entity of type: Thing
Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion.
rdf:langString
rdf:langString
Juno Therapeutics
rdf:langString
Juno Therapeutics Inc
rdf:langString
Juno Therapeutics Inc
xsd:integer
47030169
xsd:integer
1122468143
xsd:integer
2013
rdf:langString
Hans Bishop
rdf:langString
Hyam Levitsky, M.D.
rdf:langString
Mark Gilbert, M.D.
rdf:langString
Steve Harr, M.D.
rdf:langString
Seattle, WA
rdf:langString
File:Juno Therapeutics logo.jpg
rdf:langString
Subsidiary
rdf:langString
Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene.
xsd:nonNegativeInteger
9277
xsd:gYear
2013